The GBp 1250 bullish trend line is in line of sight.

From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year.

Technically, the security shows a bullish configuration on all time scales. Prices operates in an upward channel and seems to be able to quickly reach the upper limit.

In consequence, investors can take a long position in Hikma Pharmaceuticals with a first target price at GBp 1250. Then, a new bullish fluctuation could lead the security toward the GBp 1280 long term resistance. A stop loss will be set under the GBp 1176.